These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32147955)

  • 1. Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.
    Amedro P; Gavotto A; Abassi H; Picot MC; Matecki S; Malekzadeh-Milani S; Levy M; Ladouceur M; Ovaert C; Aldebert P; Thambo JB; Fraisse A; Humbert M; Cohen S; Baruteau AE; Karsenty C; Bonnet D; Hascoet S;
    ESC Heart Fail; 2020 Apr; 7(2):747-756. PubMed ID: 32147955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R
    Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between three-dimensional echocardiography and cardiopulmonary fitness in patients with univentricular heart: A cross-sectional multicentre prospective study.
    Femenia V; Pommier V; Huguet H; Iriart X; Picot MC; Bredy C; Lorca L; De La Villeon G; Guillaumont S; Pasquie JL; Matecki S; Roubertie F; Leobon B; Thambo JB; Jalal Z; Thomas J; Mouton JB; Avesani M; Amedro P
    Arch Cardiovasc Dis; 2023 Apr; 116(4):202-209. PubMed ID: 36966111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro.
    Garcia AM; Nakano SJ; Karimpour-Fard A; Nunley K; Blain-Nelson P; Stafford NM; Stauffer BL; Sucharov CC; Miyamoto SD
    Circ Heart Fail; 2018 Sep; 11(9):e004571. PubMed ID: 30354365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The V̇e/V̇co
    Gavotto A; Huguet H; Picot MC; Guillaumont S; Matecki S; Amedro P
    J Appl Physiol (1985); 2020 Nov; 129(5):1102-1110. PubMed ID: 32909919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
    Lewis GD; Lachmann J; Camuso J; Lepore JJ; Shin J; Martinovic ME; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Jan; 115(1):59-66. PubMed ID: 17179022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
    Wu X; Yang T; Zhou Q; Li S; Huang L
    Eur J Heart Fail; 2014 Apr; 16(4):444-53. PubMed ID: 24464734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
    Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
    Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a centre and home-based cardiac rehabilitation program on the quality of life of teenagers and young adults with congenital heart disease: The QUALI-REHAB study rationale, design and methods.
    Amedro P; Gavotto A; Legendre A; Lavastre K; Bredy C; De La Villeon G; Matecki S; Vandenberghe D; Ladeveze M; Bajolle F; Bosser G; Bouvaist H; Brosset P; Cohen L; Cohen S; Corone S; Dauphin C; Dulac Y; Hascoet S; Iriart X; Ladouceur M; Mace L; Neagu OA; Ovaert C; Picot MC; Poirette L; Sidney F; Soullier C; Thambo JB; Combes N; Bonnet D; Guillaumont S
    Int J Cardiol; 2019 May; 283():112-118. PubMed ID: 30616811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO
    Klaassen SHC; Liu LCY; Hummel YM; Damman K; van der Meer P; Voors AA; Hoendermis ES; van Veldhuisen DJ
    J Card Fail; 2017 Nov; 23(11):777-782. PubMed ID: 28736291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiopulmonary exercise response in patients with left ventricular dysfunction or heart failure: a noninvasive study by gas exchange and impedance cardiography monitoring.
    Romano M; Monteforte I; Cardei S; Lerro A; Celano G; Mazza A; Capaldo M; Paglia N; Campopiano A; Lembo G; Trimarco B; Condorelli M
    Cardiology; 1996; 87(2):147-52. PubMed ID: 8653732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of right and left ventricular function in the ventilatory response to exercise in chronic heart failure.
    Clark AL; Swan JW; Laney R; Connelly M; Somerville J; Coats AJ
    Circulation; 1994 May; 89(5):2062-9. PubMed ID: 8181130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure.
    Guazzi M; De Vita S; Cardano P; Barlera S; Guazzi MD
    Am Heart J; 2003 Sep; 146(3):542-8. PubMed ID: 12947376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise physiology in pulmonary hypertension patients with and without congenital heart disease.
    Righini FM; Apostolo A; Heck PB; Farina S; Hager A; Correale M; Badagliacca R; Barbieri S; Sciomer S; Agostoni P
    Eur J Prev Cardiol; 2019 Jan; 26(1):86-93. PubMed ID: 30354746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.